	US 11,779,562 B2
	Cannabis composition
Harry Karelis, Perth (AU); Mara Gordon, Bodega Bay, CA (US); Stewart Smith, Bodega Bay, CA (US); and Stewart Washer, Stirling (AU)
Assigned to Zelira Therapeutics Operations Pty Ltd, Perth (AU)
Filed by ZELIRA THERAPEUTICS OPERATIONS PTY LTD, Perth (AU)
Filed on Jul. 14, 2022, as Appl. No. 17/865,024.
Application 17/865,024 is a continuation of application No. 16/322,447, abandoned, previously published as PCT/AU2017/050814, filed on Aug. 3, 2017.
Claims priority of provisional application 62/370,304, filed on Aug. 3, 2016.
Prior Publication US 2022/0347155 A1, Nov. 3, 2022
Int. Cl. A61K 31/352 (2006.01); A61P 25/20 (2006.01); A61K 31/05 (2006.01); A61K 47/06 (2006.01); A61K 36/185 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 31/05 (2013.01); A61K 47/06 (2013.01); A61P 25/20 (2018.01); A61K 36/185 (2013.01)]

10 Claims

1. A pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising:

Δ⁹-Tetrahydrocannabinol (THC) in an amount of from 50% to 90% by weight of the Cannabis extract;

Cannabidiol (CBD) in an amount of up to 10% by weight of the Cannabis extract;

Cannabinol (CBN) in an amount of up to 10% by weight of the Cannabis extract; and

a terpene fraction in an amount of more than 1% by weight of the Cannabis extract, the terpene fraction comprising:

a nerolidol being absent or in an amount of from about 0.01% to about 20% by weight of the terpene fraction;

beta-myrcene in an amount of up to 40% by weight of the terpene fraction;

linalool in an amount of at least 5% by weight of the terpene fraction;

alpha-pinene in an amount of from 0.001% to 20% by weight of the terpene fraction; and

beta-pinene in an amount of from 0.001% to 80% by weight of the terpene fraction.